Bumper Offer - Urjas oil Just @ Rs. 1 X
SUCRAL-O SUSPENSION 200ML, a prescription drug, is manufactured in various forms such as Suspension. Peptic Ulcer are some of its major therapeutic uses. Secondary and off-label uses of SUCRAL-O SUSPENSION 200ML have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of SUCRAL-O SUSPENSION 200ML. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
SUCRAL-O SUSPENSION 200ML also has some side effects, the most common being Constipation. Besides the aforementioned side effects, there are other adverse effects of SUCRAL-O SUSPENSION 200ML as well, which are listed below. These side effects of SUCRAL-O SUSPENSION 200ML are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of SUCRAL-O SUSPENSION 200ML is Unknown for pregnant women and Unknown for women who are breastfeeding. Warnings related to SUCRAL-O SUSPENSION 200ML's effects on the liver, heart and kidney, if any, have been listed below.
SUCRAL-O SUSPENSION 200ML is not recommended if you suffer from certain medical conditions as it can have adverse effects. Diabetes are examples of such conditions. Other contraindications of SUCRAL-O SUSPENSION 200ML have been discussed in the sections ahead.
Additionally, SUCRAL-O SUSPENSION 200ML may also adversely react with other medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking SUCRAL-O SUSPENSION 200ML is considered not safe while driving, and is not addictive.
SUCRAL-O SUSPENSION 200ML is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult |
|
| Geriatric |
|
| 13 - 18 years (Adolescent) |
|
| 2 - 12 years (Child) |
|
Based on research, the following side effects have been observed when SUCRAL-O SUSPENSION 200ML is used -
Moderate
Mild
Common
Is the use of SUCRAL-O SUSPENSION 200ML safe for pregnant women?
The effects of Sucral on pregnant women are unknown since no research has been done to ascertain it yet.
Is the use of SUCRAL-O SUSPENSION 200ML safe during breastfeeding?
Information about safety of Sucral for women who are breastfeeding is not available since scientific research on this is yet to be done.
What is the effect of SUCRAL-O SUSPENSION 200ML on the Kidneys?
Sucral rarely harms the kidneys.
What is the effect of SUCRAL-O SUSPENSION 200ML on the Liver?
Sucral does not damage the liver.
What is the effect of SUCRAL-O SUSPENSION 200ML on the Heart?
You can take Sucral without any fear of damage to the heart.
SUCRAL-O SUSPENSION 200ML should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take SUCRAL-O SUSPENSION 200ML unless your doctor advises you to do so -
Is this SUCRAL-O SUSPENSION 200ML habit forming or addictive?
SUCRAL-O SUSPENSION 200ML is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
After taking SUCRAL-O SUSPENSION 200ML you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
SUCRAL-O SUSPENSION 200ML is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking SUCRAL-O SUSPENSION 200ML for mental disorders.
Interaction between Food and SUCRAL-O SUSPENSION 200ML
It is safe to take SUCRAL-O SUSPENSION 200ML with food.
Interaction between Alcohol and SUCRAL-O SUSPENSION 200ML
Information about the interaction of SUCRAL-O SUSPENSION 200ML and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Carafate
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 656-657
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1154-1155